Bárbara Melão

GREAT 1st DAY OF #PROSCA24
Currently going on in Vienna🇦🇹
Perfect way to follow up 2 Amazing meetings in #RENALC24 @ #BLADDR24 w/ OVER 10 million impressions on X ‼️

Kudos to Mirrors of Medicine
@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

29.11.2024 11:01 — 👍 6    🔁 4    💬 0    📌 1

#PROSCA24
✨PSMA is the imaging choice in BCR
✨impact on clinical management ~60%
✨PPV 85-90%
✨different PSMA tracers with different detection rate
✨PROMISE registry to build monogram to predict survival: in BCR setting the nomogram had a strong correlation with survival
‼️for MDT: use PSMA11

29.11.2024 16:54 — 👍 5    🔁 3    💬 0    📌 0

Day One of #PROSCA24
Presenter: Dr Alfred Haidenberger
Biochemical recurrence following local therapy
Radiosurgery for Recurrent Prostate Cancer

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

29.11.2024 13:55 — 👍 7    🔁 4    💬 0    📌 0

One size doesn’t fit all‼️
✨Improved RT delivery
✨ADT: consider life expectancy, baseline comorbidities
✨ADT duration: 18 months may be enough; genomic classifiers could better tailor duration
✨Intensification (ARPI) in very high-risk patients

29.11.2024 16:53 — 👍 6    🔁 2    💬 0    📌 0

Gleason 6: should we keep calling it cancer?
Eva Compérat

Yes‼️ It’s cancer
✨People may die from GS 6
✨Up to 80% heterogeneous
✨We can not predict those who will progress
‼️Patient will be much more willing to be followed
@oncoalert.bsky.social
@drnataliagandur.bsky.social
@yukselurun.bsky.social

29.11.2024 16:50 — 👍 4    🔁 3    💬 0    📌 0

Gleason 6: should we keep calling it cancer?Roderick van den Bergh
No‼️ But we need surveillance
✨It doesn’t metastasize
✨14% upgrading
✨12-24% true progression
‼️Use of risk factors could estimate the risk of true cancer
@oncoalert.bsky.social @drnataliagandur.bsky.social @yukselurun.bsky.social

29.11.2024 16:48 — 👍 2    🔁 2    💬 0    📌 0

#PROSCA24 livestream starting with ADT and cardiovascular risk in #ProstateCancer. Suma Konety

‼️ADT increases CV risk => development of metabolic syndrome
‼️Control of blood pressure and cholesterol is mandatory = high genomic diversity

@oncoalert.bsky.social @drnataliagandur.bsky.social

29.11.2024 16:45 — 👍 3    🔁 2    💬 0    📌 0

Day One of #RENALC24
Dr. Philippe BARTHÉLÉMY
Looking ahead: RCC management in 2025

Importance of precision medicine, optimization of combination therapies & need for new biomarkers to improve outcomes.
#KidneyCancer

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social

26.11.2024 16:46 — 👍 8    🔁 7    💬 0    📌 1

2 Million Impressions on the first ever #RenalC24
Congratulations to our Collaborators at Mirrors of Medicine
JOIN US TOMORROW for Day One of #BLADDR24
WE ARE @OncoAlert 🚨

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@yukselurun.bsky.social
@achoud72.bsky.social

26.11.2024 17:24 — 👍 11    🔁 4    💬 0    📌 1

Elucidating acquired PARP inhibitor resistance in advanced prostate cancer PARP inhibition (PARPi) has anti-tumor activity against castration-resistant prostate cancer (CRPC) with homologous recombination repair (HRR) defects…

Elucidating acquired PARP inh resistance
sciencedirect.com/science/arti...

Highlights emergence of resistance in met CR #ProstateCancer tx w/ PARP inh💊, particularly in BRCA2 & PALB2 mutations🧬

@drnataliagandur.bsky.social
@barbaramelao.bsky.social
@achoud72.bsky.social
@yukselurun.bsky.social

26.11.2024 18:04 — 👍 22    🔁 8    💬 0    📌 0

Honored to be part of this team
@oncoalert.bsky.social

22.11.2024 01:12 — 👍 2    🔁 1    💬 0    📌 0